116 related articles for article (PubMed ID: 22098352)
1. Isoform-specific inhibitors of ACATs: recent advances and promising developments.
Ohshiro T; Tomoda H
Future Med Chem; 2011 Dec; 3(16):2039-61. PubMed ID: 22098352
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of pyripyropene derivatives in inhibition toward acyl-CoA:cholesterol acyltransferase 2 isozyme.
Ohshiro T; Ohte S; Matsuda D; Ohtawa M; Nagamitsu T; Sunazuka T; Harigaya Y; Rudel LL; Omura S; Tomoda H
J Antibiot (Tokyo); 2008 Aug; 61(8):503-8. PubMed ID: 18997389
[TBL] [Abstract][Full Text] [Related]
3. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
Tomoda H; Doi T
Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of microbial acyl-CoA: cholesterol acyltransferase inhibitors toward isozymes.
Ohshiro T; Rudel LL; Omura S; Tomoda H
J Antibiot (Tokyo); 2007 Jan; 60(1):43-51. PubMed ID: 17390588
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 1.
Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Omura S; Tomoda H; Nagamitsu T
Bioorg Med Chem Lett; 2013 Mar; 23(5):1285-7. PubMed ID: 23369538
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 3.
Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Ōmura S; Tomoda H; Nagamitsu T
Bioorg Med Chem Lett; 2013 Jul; 23(13):3798-801. PubMed ID: 23711919
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
López-Farré AJ; Sacristán D; Zamorano-León JJ; San-Martín N; Macaya C
Cardiovasc Ther; 2008; 26(1):65-74. PubMed ID: 18466422
[TBL] [Abstract][Full Text] [Related]
8. Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A.
Das A; Davis MA; Tomoda H; Omura S; Rudel LL
J Biol Chem; 2008 Apr; 283(16):10453-60. PubMed ID: 18285335
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
Tomoda H; Omura S
Pharmacol Ther; 2007 Sep; 115(3):375-89. PubMed ID: 17614133
[TBL] [Abstract][Full Text] [Related]
10. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia.
Ohshiro T; Matsuda D; Sakai K; Degirolamo C; Yagyu H; Rudel LL; Omura S; Ishibashi S; Tomoda H
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1108-15. PubMed ID: 21393580
[TBL] [Abstract][Full Text] [Related]
11. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
Lada AT; Davis M; Kent C; Chapman J; Tomoda H; Omura S; Rudel LL
J Lipid Res; 2004 Feb; 45(2):378-86. PubMed ID: 14617738
[TBL] [Abstract][Full Text] [Related]
12. A critical role for the histidine residues in the catalytic function of acyl-CoA:cholesterol acyltransferase catalysis: evidence for catalytic difference between ACAT1 and ACAT2.
An S; Cho KH; Lee WS; Lee JO; Paik YK; Jeong TS
FEBS Lett; 2006 May; 580(11):2741-9. PubMed ID: 16647063
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of acyl-CoA:cholesterol acyltransferase 2 isozyme by flavasperone and sterigmatocystin from Aspergillus species.
Sakai K; Ohte S; Ohshiro T; Matsuda D; Masuma R; Rudel LL; Tomoda H
J Antibiot (Tokyo); 2008 Sep; 61(9):568-72. PubMed ID: 19160525
[TBL] [Abstract][Full Text] [Related]
14. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
Rudel LL; Lee RG; Parini P
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1112-8. PubMed ID: 15831806
[TBL] [Abstract][Full Text] [Related]
15. New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.
Ohshiro T; Ohtawa M; Nagamitsu T; Matsuda D; Yagyu H; Davis MA; Rudel LL; Ishibashi S; Tomoda H
J Pharmacol Exp Ther; 2015 Nov; 355(2):299-307. PubMed ID: 26338984
[TBL] [Abstract][Full Text] [Related]
16. Penicillium griseofulvum F1959, high-production strain of pyripyropene a, specific inhibitor of acyl-CoA: cholesterol acyltransferase 2.
Choi JH; Rho MC; Lee SW; Choi JN; Lee HJ; Bae KS; Kim K; Kim YK
J Microbiol Biotechnol; 2008 Oct; 18(10):1663-5. PubMed ID: 18955816
[TBL] [Abstract][Full Text] [Related]
17. New verticilides, inhibitors of acyl-CoA:cholesterol acyltransferase, produced by Verticillium sp. FKI-2679.
Ohshiro T; Matsuda D; Kazuhiro T; Uchida R; Nonaka K; Masuma R; Tomoda H
J Antibiot (Tokyo); 2012 May; 65(5):255-62. PubMed ID: 22415459
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship studies on a novel series of naphthylidinoylureas as inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT).
Ohnuma S; Muraoka M; Ioriya K; Ohashi N
Bioorg Med Chem Lett; 2004 Mar; 14(5):1309-11. PubMed ID: 14980688
[TBL] [Abstract][Full Text] [Related]
19. The selectivity of beauveriolide derivatives in inhibition toward the two isozymes of acyl-CoA: cholesterol acyltransferase.
Ohshiro T; Matsuda D; Nagai K; Doi T; Sunazuka T; Takahashi T; Rudel LL; Omura S; Tomoda H
Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):377-81. PubMed ID: 19336931
[TBL] [Abstract][Full Text] [Related]
20. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors.
Meuwese MC; Franssen R; Stroes ES; Kastelein JJ
Curr Opin Lipidol; 2006 Aug; 17(4):426-30. PubMed ID: 16832167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
